Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Conditions:   Melanoma;   Renal Cell Carcinoma;   NSCLC;   Hepatocellular Carcinoma;   Urothelial Cancer;   Gastric Adenocarcinoma;   HNSCC;   Esophageal Adenocarcinoma;   Microsatellite Instability-High Solid Malignant Tumor
Interventions:   Drug: Nivolumab or Pembrolizumab (dependent upon approved indication);   Drug: Metformin;   Drug: Rosiglitazone
Sponsor:   Dan Zandberg
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2020 / by / in
Comments